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A B S T RA C T A new kindred with asymptomatic
hypobetalipoproteinemia is reported. The proband, age
67, differs from previously described cases in several
respects: (a) unusually low levels of low density lipo-
protein (LDL) cholesterol (4-8 mg/dl); (b) normal tri-
glyceride levels; (c) low levels of high density lipopro-
tein; (d) mild fat malabsorption; and (e) a defect in
chylomicron clearance. Ona high-carbohydrate diet his
plasma triglyceride levels, instead of rising, actually
fell. Turnover of triglycerides in very low density lipo-
proteins (VLDL) was low (2.8 mg/kg per h). Fractional
catabolic rate of LDL protein was just above the normal
range (0.655/d) but net turnover was < 10%of nornal (0.65
mg/kg per d). The half-life of his chylomicrons was 29
min, five times the normal value. Postheparin lipopro-
tein lipase activity was normal and apolipoprotein C-II,
the activator protein for lipoprotein lipase, was present
and functional. Apolipoprotein C-l1, however, was
not detected in the VLDL fraction, a finding previously
reported in patients with abetalipoproteinemia. Fecal
excretion of cholesterol was almost twice normal; total
sterol balance was increased by -40%. The unusual
features in the proband that distinguish him from pre-
viously described cases and from his affected first-degree
relatives suggested that, in addition to the basic gene
defect affecting LDL metabolism, he might have a
second abnormality affecting clearance of chylomicrons
and VLDL. The ratio of apolipoprotein E3 to E2 in his
VLDL fraction was 0.93, just below the lower limit of
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normal, suggesting heterozygosity for E3 deficiency.
Whether or not this contributes to his hypertriglyc-
eridemia remains to be established.
INTRODUCTION
Extremely low levels of plasma ,8-lipoproteins are en-
countered in at least two distinct inherited disease
states (1). In "abetalipoproteinemia" no apoprotein B
is detected in the plasma even by the most sensitive
immunochemical assays. Ordinary methods fail to
reveal low density lipoprotein (LDL),1 very low density
lipoprotein (VLDL), or chylomicrons. By concentrating
the fraction with d < 1.063 it is possible to demonstrate
lipoproteins but these are abnormal in composition and
structure, i.e., they do not represent normal LDL or
VLDL (1-4). This apparently total deficiency of lipo-
proteins containing apoprotein B is associated with a
severe clinical syndrome, usually apparent in infancy
(5). The syndrome is characterized by fat malabsorp-
tion, retinitis pigmentosa, neurologic involvement (in-
cluding cerebellar ataxia and mental retardation), and
acanthocytosis. The inheritance pattern is autosomal
recessive, with parents having normal lipoprotein levels
and none of the clinical manifestations.
In "hypobetalipoproteinemia" plasma LDL can be
demonstrated but the levels are sharply reduced. This
partial deficiency of LDL is not associated with the
severe clinical manifestations characteristic of abeta-
lipoproteinemia. Most patients are totally asymptomatic
1 Abbreviations used in this paper: apoA, B, C, and E, apo-
lipoproteins A, B, C, and E; HDL, high density lipoprotein;
IDL, intermediate density lipoprotein; LDL, low density lipo-
protein; VLDL, very low density lipoprotein.
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and the diagnosis is usually made by chance during a
routine clinical work-up or in screening programs. Fat
absorption is normal or only marginally impaired; acan-
thocytes are rarely seen; growth and development in
infancy and childhood are almost always normal. A
few patients have had neurological signs and symptoms
but the other hypobetalipoproteinemic members of
these kindreds were unaffected. The nature of the re-
lationship between the neurologic changes and the
hypobetalipoproteinemia remains unclear. This dis-
order is inherited in an autosomal dominant pattern.
Recently it has become clear that a double dose of the
abnormal allele causing hypobetalipoproteinemia can
produce a severe clinical picture not readily distin-
guishable from that of abetalipoproteinemia (6, 7).
However, the clearly dominant inheritance of hypo-
betalipoproteinemia in these kindreds indicates that
homozygous hypobetalipoproteinemia represents a
mutation distinct from that in abetalipoproteinemia.
In this paper we present the results of intensive
studies in an asymptomatic man in his seventh decade
with a familial hypobetalipoproteinemic syndrome dif-
ferent from those previously reported in a number of
respects: (a) extremely low LDL levels (4-8 mg LDL
cholesterol/dl); (b) niormal triglyceride levels; (c) low
high density lipoprotein levels; (d) mild fat malabsorp-
tion; and (e) a chylomicron clearance defect.
METHODS
Patient. H.J.B., a retired Navy chaplain, was first seen in
the La Jolla Lipid Research Clinic in September 1975 at age
64. He was referred because total plasma cholesterol, de-
termined in the course of a routine screening examination,
was 47 mg/dl. He has enjoyed remarkably good health.
There was a history of labile hypertension during World War
II but this never required treatment. The patient underwent
thyroid surgery but has never been on replacemnent therapy
and had a normal thyroxine level when referred. There was no
history of childhood illness; no history of diarrhea or abnormal
stools; no history of neurologic dysfunction, including muscle
weakness, ataxia, paresthesias, anesthesia, or cranial nerve
problems. Dietary history was unremarkable except that the
patient prefers vegetables and avoids pastries, candies, and
sweets. He does not smoke and is taking no medications.
When first seen in the fall of 1975 the proband had a fasting
plasma that was slightly but definitely turbid. Lipoprotein
quantification using standard Lipid Research Clinic methods
(8) were as follows: total plasma cholesterol, 34 mg/dl;
high density lipoprotein (HDL) cholesterol, 19 mg/dl;
LDL cholesterol, 7 mg/dl; VLDL cholesterol, 8 mg/dl;
total plasma triglycerides, 117 mg/dl. In December 1975
total plasma cholesterol was 34 mg/dl; HDL cholesterol,
23 mg/dl; LDL cholesterol, 3 mg/dl; VLDL cholesterol,
10 mg/dl. Fasting plasma triglycerides were 67 mg/dl
but the plasma was again turbid even though the patient
had been fasting for 17 h. Chylomicrons were demonstrated
both by the presence of an opaque surface layer on plasma
stored overnight in the refrigerator and by a lipid-staining
band at the origin on agarose gel electrophoresis.
The patient was admitted to the Veteran's Administration
Hospital, San Diego, on 6 May 1976. Physical examination
revealed a well-nourished man 5 ft 6 in. tall and weighing 171
lb. Pulse, 72/min and regular; blood pressure, 160/90. There
was no retinal pigmentation. Hearing was normal for his age.
Heart and lungs were within normal limits. The liver was
smooth and nontender, palpable 4 cm below the right costal
margin, with a total liver span of 15 cm. The spleen was not
felt. Rectal examination revealed an enlarged prostate con-
sistent with benign prostatic hypertrophy. Neurological ex-
amination, performed by Professor W. C. Wiederholt, Chair-
person of Neurosciences, was within normal limits. Specifically,
there were no abnormal pyramidal, cerebellar, or posterior
column signs and no peripheral neuropathy.
The following laboratory values were obtained: hemoglo-
bin, 14.2 g/dl; hematocrit, 42.6%. Erythrocyte indices were
normal and the morphology of most cells was normal except
that a rare acanthocyte was noted. Leukocytes, 4,000/mm3 with
normal differential count. Fasting plasma glucose, 112 mg/dl;
2-h postprandial plasma glucose, 136 mg/dl. Normal values
were found for blood urea nitrogen, uric acid, calcium, phos-
phorus, iron, electrolytes, creatinine, total bilirubin, alkaline
phosphatase, lactic dehydrogenase, glutamic oxaloacetic
transaminase, glutamic pyruvic transaminase, creatine phos-
phokinase, bromosulfonphthalein retention, thyroxine, and
free thyroxine index. Urinalysis was negative. Plasma protein
electrophoresis was normal. Chest x ray was normal. Abdominal
x ray showed multiple radiopaque shadows in the right upper
quadrant consistent with cholelithiasis; abdominal echo-
graphic studies confirmed the presence of gallstones.
Electrocardiogram showed a normal sinus rhythm. There
was left axis deviation and evidence of old anteroseptal myo-
cardial infarction. Additional questioning elicited no history
suggestive of infarction. A later exercise electrocardiogram
(heart rate 160) elicited no symptoms and no ischemic signs.
Fecal fat in a 3-d stool collection was 13 g/d (dietary fat
100 g/d). Additional measurements on four 2-d stool collec-
tions, made in the course of measurements of sterol excretion,
gave the following values for fat excretion: 15.3, 16.9, and
14.8 g/d.
Metabolic studies. The patient was studied in the Special
Diagnostic and Treatment Unit of the Veteran's Administra-
tion Hospital and as anl outpatient. He gave informed consent
for all investigationis.
The patient was hospitalized twice. During the first hospi-
talization of 3 wk he was fed a mixed solid food and liquid
formula diet which has been described previously in detail (9).
The diet provided 40% of calories as fat (in the form of lard),
45% of calories as carbohydrate, and 15% as protein; daily
cholesterol intake was 93 mg/d. During the second hospitaliza-
tion of 2 wk, the patient took an ad lib. solid food diet pro-
viding =40% of calories in the form of fat. After discharge,
the patient was instructed to follow a low-fat diet for 3 wk. This
diet conisisted of low-fat vegetables, fruits, and skimmed milk;
fat contenit was estimated to provide <10% of calories.
Plasma cholesterol and triglycerides were analyzed using
a Technicon AutoAnalyzer (model II, Technicon Instruments
Corp., Tarrytown, N. Y.) (8). Lipoprotein fractions were iso-
lated by preparative ultracentrifugation usinlg the methods of
Havel et al. (10) unless otherwise specified. Electron micros-
copy of plasma lipoprotein fractions was carried out on nega-
tively stained preparations prepared as described elsewhere (11).
Cholesterol balance studies were carried out according to
methods previously described (12-14). Stools were collected
for the last 10 d of the first hospitalization and 2-d pools were
analyzed. Fecal neutral steroids and acidic steroids were de-
terminied by gas-li(quid chromatography. To correct for losses
of nieutral steroids, B-sitosterol was given in smiiall doses as an
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internal standard and excretion of steroids was corrected for
variations in fecal flow by use of chromic oxide as a marker.
Administration of markers was begun at the time of hospitaliza-
tion to ensure equilibration by the time stool collections were
begun.
Qualitative tests for apolipoproteins were carried out by
radial immunodiffusion (15) and by polyacrylamide gel elec-
trophoresis (16). Quantitative mseasurements of apolipoprotein
levels in whole plasma and in ultracentrifugal fractions were
carried out by radial immunodiffusion and by double-antibody
radioimmunoassay using methods previously described (17,
18). Isoelectric focusing for determinations of apolipoprotein
(apo)E3/apoE2 ratios was done by the method of Wamick et al.
(19). Total protein in fractions was determined by the method
of Lowry et al. (20).
For measurement of LDL apoprotein turnover, LDL was
prepared from the plasma of a normal donor negative for hepa-
titis B antigen and with a history of repeated uneventful plasma
donations in the past. The LDL fraction (d 1.019-1.063) was
iodinated with 125I-Cl by a modification of the method of
McFarlane (21) and Bilheimer et al. (22). The plasma and its
fractions were handled with sterile precautions, passed
through a 0.45-,im Millipore filter (Millipore Corp., Bedford,
Mass.), and then tested for bacterial contamination and pyro-
genicity before use. The recipient was started on KI, 900 mg/d,
just before study and maintained on that dosage throughout.
The labeled LDL (50 ,uCi) was injected after an overnight
fast. Blood samples were drawn at frequent intervals during
the first 24 h and daily thereafter. Previous studies have shown
that little or no 125I-LDL radioactivity is transferred to other
lipoprotein fractions and analyses were based therefore on
total radioactivity per milliliter of plasma. The plasma radio-
activity decay curve was analyzed by the method of Matthews
(23) for determination of fractional catabolic rate.
For 36 h before measurement of VLDL triglyceride turn-
over, fat was deleted from the patient's diet to eliminate pos-
sible ambiguities owing to chylomicronemia. Carbohydrate
and protein intake were continued at the same level in fre-
quent small feedings of liquid formula (24). For determination
of the turnover of VLDL triglycerides, ['4C]glycerol was in-
jected intravenously and blood samples were taken at intervals
for isolation of the VLDL fraction. Lipids were extracted from
each sample using isopropanol and phospholipids were ad-
sorbed onto silicic acid. After saponification, the nonsaponi-
fiable lipids were extracted into heptane. Free glycerol was
determined in one aliquot of the aqueous phase and radio-
activity was assayed by liquid scintillation counting of a
second aliquot. Turnover was determined using multicom-
partmental analysis as described by Zech et al. (25).
Fibroblast cultures were initiated from a skin biopsy taken
from the suprascapular region at the time of the first hospitali-
zation. The cells were studied at the seventh passage. Methods
for maintaining the cells in culture have been previously de-
scribed (26). LDL isolated from pooled normal human plasma
was iodinated as described above and its surface binding,
internalization, and degradation were determined in normal
cultured fibroblasts and in the patient's fibroblasts. In addi-
tion, competition between LDL isolated from the patient and
iodinated normal LDL was studied and compared with com-
petition between unlabeled LDL from a normal donor and
iodinated LDL prepared from pooled normal human plasma.
RESULTS
Plasma lipids and lipo proteins. Total plasma cho-
lesterol and triglyceride values during three different
dietary periods in the course of metabolic studies are
TABLE I
Effects of Diet on Plasma Cholesterol
and Triglycerides in Patient HJ.B.




solid foods (40% calories
from fat) 40+1.5 (6)* 91+14 (6)
Ad lib. solid foods (-40% of
calories from fat) 42+2.8 (4)t 103±+16 (4)
Low-fat diet (-55% of calories
from fat, 80% from carbo-
hydrates) 33± 1.9 (5)§ 61±+ 11 (5)
* Six determinations over the last 21 d of a 26-d period. Mean
+SEM.
t Four determinations over the last 9 d of a 14-d period. Mean
±SEM.
§ Five determinations over the last 15 d of a 21-d period. Mean
±SEM.
shown in Table I. Total plasma cholesterol remained
very low on all diets, possibly somewhat lower on the
low-fat diet. The range was from 28 to 48 mg/dl. Total
plasma triglycerides were more variable. The mean
values on diets containing 40% of calories as fat were
within the normal range. Interestingly, the low-fat diet,
which provided -80% of calories in the form of carbo-
hydrate, was not associated with a rise in plasma tri-
glycerides; in fact, the mean triglyceride value on this
high-carbohydrate diet was significantly lower than on
the diets providing 40% of calories as fat.
While on the low-fat diet, the patient was given an
oral meal of 100 g of safflower oil. The cholesterol and
triglyceride content of whole plasma and of ultracen-
trifugally isolated lipoprotein fractions in the fasting
state and at intervals after the fat meal are shown in
Table II. Total plasma triglyceride rose considerably,
TABLE II
Plasma Lipids in Lipoprotein Fractions
after a 100-g Oral Fat Load
Whole Chylo- IDL/
plasma microns VLDL LDL* HDL
Time Ct TG C TG C TG C TG C TG
h mgldl
Zero 34 38 0 2 7 24 8 5 16 4
4 36 68 0 29 4 13 3 11 23 15
5 31 137 2 86 4 21 3 13 22 17
6 33 234 4 191 3 19 2 10 23 14
* IDLILDL = fraction of d 1.006 - 1.063.
t C, cholesterol; TG, triglycerides.
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from 38 mg/dl initially to a peak of 234 mg/dl at 6 h. Most
of this elevation was accounted for by the triglyceride
content of the chylomicron fraction. Total plasma cho-
lesterol did not change significantly. Triglyceride con-
tent of the VLDL fraction did not increase. However,
there were small but consistent increases in the tri-
glyceride content of the intermediate density lipopro-
tein (IDL)/LDL fraction (d 1.006-1.063) and of the
HDL fraction.
Apolipoproteins. On two occasions the total apoB
content of whole plasma determined by radioimmunoas-
say, was found to be 5.8 and 6.6 mg/dl, respectively. The
apoB content of the lipoprotein subfractions is shown
in Table III. The apoB content in the d-1.006-1.063
fraction was 2.4 mg/dl, <3% of the normal value. The
total protein content of this fraction was 3 mg/dl, in
reasonably good agreement with the apoB content de-
termined by radioimmunoassay.
The VLDL fraction contained only 0.9 mg/dl of apoB
despite the relatively normal total triglyceride concen-
tration in the VLDL fraction, i.e., the apoB content was
abnormally low. The total protein in this fraction was
2.8 mg/dl, suggesting that apoB accounted for approxi-
mately one-third of the total protein, in good agreement
with published values for normal VLDL (27). As shown
in Fig. 1 the VLDL fraction was relatively enriched in
apoE ("arginine-rich protein"). The band running just
behind apoE has not been further characterized. Iso-
electric focusing on two occasions gave apoE3/apoE2
ratios of 0.96 to 0.90. Ratios below 1.0 are considered
to be in the intermediate range found in subjects het-
erozygous for apoE3 deficiency (19). It is also evident
from Fig. 1 that there is a marked deficiency of apoC-III,
accompanied by a relative increase in apoC-III2.
TABLE III
Apoprotein Concentrations in Whole Plasma
and in Lipoprotein Fractions
Apoprotein and Concentration
plasma fraction in H.J.B. Normal subjects*
Apo B





d > 1.25 0.3
Apo A-I
Whole plasma 77 120±20
Apo A-II
Whole plasma 17 33±5
Mean values for normolipidemic subjects determined in sur-
veys by the Northwest Lipid Research Clinic (17, 18).
t SD.
N H.B. N HB. N H.B.
VLDL VLDL LDL LDL HDL HDL






FIGURE 1 Urea-polyacrylamide gel electrophoresis of the
apoproteins in VLDL, LDL, and HDL fractions from patient
H.J.B.'s fasting plasma.
The HDLfraction (d 1.063-1.21) contained 2.2 mg/dl
of apoB, a value not different from that found in the
same fraction isolated from normal individuals (2.0
mg/dl) and possibly reflecting the presence of Lp (a)
(17). The concentrations of apoA-I and apoA-II were
both lower than the normal values (77 vs. 120 mg/dl and
17 vs. 33 mg/dl, respectively (18). As shown in Fig. 1,
the pattern of apoproteins in HDL was normal.
Properties and turnover of VLDL. On electron
microscopy the VLDL fraction was not unusual except
for the presence of some particles with diameters larger
than those usually found in this fraction. The mean
diameter was 375+127 A (SD). Kane et al. (28) report a
mean VLDL diameter of 364 A in 12 normal subjects
but 98% of the molecules had diameters between 250
and 500 A; in the present case 9%had diameters >500
A, i.e., there was considerable skewing to the right.
The larger particles may represent residual chylomi-
crons. Paper and agarose gel electrophoresis showed a
predominant pre-,8-band with some trailing to the origin.
Turnover of the triglycerides in VLDL was deter-
mined by injecting [3Hlglycerol and following the spe-
cific radioactivity of the glycerol moiety in VLDL tri-
glycerides as a function of time (24, 25). The peak of the
specific radioactivity curve was delayed and only m25%
of the value reached in normolipidemic subjects. The
rate of decay was also much slower. From multicom-
partmental kinetic analysis generously carried out for
us by Dr. Loren Zech and Dr. Mones Berman (National
Institutes of Health), the production rate of VLDL tri-
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glycerides was estimated to be 2.8 mg/kg per h, far
below the value of 11.3+3.9 (SD) mg/kg per h found
in 18 normal subjects (25). Fractional catabolic rate,
0.11 h, was also low (normal, 0.162±0.008 [SD]).
Properties and turnover of LDL. The d-1.019-
1.063 fraction was prepared from 84 ml of plasma. Gel
electrophoresis showed a single band with beta mobil-
ity and radial immunodiffusion gave a line of apparent
identity with normal LDL.
This preparation of LDL was functionally compared
with normal LDL by examining its interaction with the
high affinity LDL receptor site on the membrane of
normal human fibroblasts (29). The binding, internali-
zation, and degradation of 1251-labeled normal LDL was
determined as previously described (26) in the presence
or in the absence of added unlabeled LDL either from
a normal subject or from H.J.B. As shown in Fig. 2, the
degradation of the labeled normal LDL was reduced
-70% by unlabeled normal LDL and to the same extent
by unlabeled LDL from H.J.B. The same was true with
respect to binding and internalization (data not shown).
Weconsidered the possibility that H.J.B. might be
degrading LDL at an abnormally high rate and studied
his own skin fibroblasts in culture from this point of
view. Degradation of LDL (10 gg/ml) by the patient's
cells grown in 10% fetal calf serum and incubated for
24 h in lipoprotein-deficient serum for 24 h was slightly
less than that seen in a normal fibroblast line. Wealso
tested whether the patient's cells would show the nor-
mal suppression of LDL receptor number in response
to LDL in the medium (29). After a 24-h exposure to
LDL (50 ,g/ml), degradation rate decreased by 79% in
















FIGURE 3 Comparison of normal skin fibroblasts and fibro-
blasts from H.J.B. with respect to suppression of LDL deg-
radation resulting from a 24-h incubation with normal LDL.
The cells were incubated with normal 125I-LDL (10 j,g/ml) for
3 h, either after a 24-h incubation in lipoprotein-deficient
medium or after an additional 24-h incubation with normal
LDL (50 jig/ml). The latter was removed by washing the mono-
layer before addition of 1251-LDL and degradation was meas-
ured as previously described.
Turnover of LDL was determined using 125I-LDL
prepared from the plasma of a normal donor. The time-
course of disappearance of 1251 from the plasma is shown
in Fig. 4, the smooth curve representing the best-fit
theoretical curve assuming the usual biexponential
decay. Fractional catabolic rate was 0.582/d. When
three exponential functions were allowed, calculated
fractional catabolic rate was 0.655/d, at the very upper
limit of values reported in normal subjects (0.26-0.63/d)




























FIGuRE 2 Inhibition of the degradation of normal 1251-LDL
(5 ,g protein/ml) by unlabeled normal LDL or unlabeled
H.J.B. LDL (40 ,ug protein/ml). Normal human skin fibroblasts
were incubated overnight in medium containing 10% lipo-
protein-deficient calf serum. The medium was changed and
normal 1251-LDL was added alone, with normal unlabeled
LDL or H.J.B. LDL. After 3 h, TCA-soluble 125I in the medium







2 4 6 8 10 12 14 16
Time (days)
FIGURE 4 Plasma 1251 disappearance curve after injection of
normal '25I-LDL. The smooth curve represents the best-fit
computer-generated curve using biexponential analysis. The
experimental data points are shown by the circles.
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size, the total calculated daily production of LDL apoB
was only 0.65 mg/kg per d (normal, 8-20 mg/kg per d).
Properties and turnover of chylomicrons. Because
of the patient's fasting chylomicronemia it was of in-
terest to assess the severity of his clearance defect. This
was done by the method of Grundy and Mok (33) in
which triglyceride is continuously administered intra-
duodenally over a 6-8-h period and plasma samples
are taken at intervals for determination of chylomicron
triglyceride levels. After 5 h, plasma triglyceride levels
reach a steady-state value. At this time the rate of
chylomicron clearance from plasma equals the rate of
chylomicron input from the intestine. Knowing the rate
of intraduodenal fat infusion (and assuming complete
absorption) and the estimated total plasma volume, one
can calculate the fractional clearance and half-life of
chylomicron triglycerides. The data in patient H.J.B.
(not shown) yielded a half-life for chylomicron triglyc-
erides of 29 min, more than five times the value in
normoglyceridemic controls (5.4±+2.9 min) (33).
The apparent chylomicron clearance defect and the
low fractional catabolic rate for VLDL triglycerides
suggested the possibility of a lipoprotein lipase de-
ficiency. However, both postheparin lipoprotein lipase
and hepatic triglyceride lipase, although below the
mean normal levels, were found to be within normal
limits (10 and 15 ,ueq FFA/ml per h, respectively, vs.
normal ranges of 8-50 and 3-100) (34). ApoC-II was
present (Fig. 1) and the patient's plasma was able to
activate lipoprotein lipase in postheparin plasma of a
normal subject.
Sterol balance. If endogenous cholesterol biosyn-
thesis by peripheral tissues is normally suppressed by
LDL, it should be abnormally high in H.J.B. As shown
in Table IV, neutral steroid excretion on a low intake of
dietary cholesterol was almost twice normal. Acidic
steroid excretion, however, was somewhat below nor-
mal so that net cholesterol balance was increased -40%.
Family study. The proband's mother, age 92, is well




subjects* H. J.B. t
nmglkg/ld
Cholesterol intake 1.8 1.24
Fecal neutral steroids 6.5±1.8§ 12.2±1.9
Fecal acidic steroids 4.9±1.8 2.5±0.52
Total fecal steroids 11.4±2.5 14.7±2.3
Sterol balance 9.6±2.3 13.5±2.3
*n = 14.
t Mean of five 2-d collections.
§ SD.
are still living and in good health at 82 and 96 yr,
respectively. The other siblings died of cancer or un-
known cause; none died of heart disease. The patient's
father died at age 86.
Lipoprotein data on the H.J.B. kindred so far avail-
able are summarized in Table V. The proband's mother
has hypobetalipoproteinemia (LDL cholesterol 46
mg/dl) but much less striking than that of H.J.B. Lipo-
protein quantification has been carried out on all living
siblings (one sister died in her 20s of rheumatic heart
disease) and both children of the proband. One brother
(A.L.B.) and one sister (J.Y.G.) have hypobetalipopro-
teinemia as striking as that in H.J.B. -LDL cholesterols
of 4 and 5 mg/dl, respectively. Both differ, however,
in having low plasma triglyceride levels and normal
HDLlevels. Neither showed fasting chylomicronemia.
Three additional siblings (J.L.P., R.W.B., and B.R.V.)
have LDL cholesterol levels below 100 mg/dl and total
plasma triglycerides below 40. The remaining three
siblings have LDL cholesterol levels in the low normal
range and normal total plasma triglyceride levels.
Both daughters have hypobetalipoproteinemia (LDL
cholesterol levels 29 and 40 mg/dl). They also have low
triglyceride levels (31 and 21 mg/dl) and normal to high
HDL cholesterol levels (67 and 51 mg/dl). Thus the
proband differs from all of the other affected members
of the kindred in having chylomicronemia, normal
plasma triglyceride levels, and low HDL levels.
None of the members of the kindred gave histories
of abnormal childhood development, steatorrhea,
visual disturbances, or neurologic symptoms.
TABLE V
Plasma Lipid Levels in the HJ.B. Kindred
Cholesterol
Total plasma
Sex Age Total plasma LDL HDL triglycerides
mg/dl
Mother
H.B.B. F 89 102 46 46 60
Proband
H.J.B. M 66 40 3-8 23 91
Siblings
A.L.B. M 47 59 5 50 29
J.Y.G. F 61 49 4 37 24
J.L.P. F 64 110 62 46 26
R.W.B. M 57 129 73 50 23
B.R.V. F 59 154 83 71 34
E.E.B. M 54 156 103 38 71
C.B. M 68 177 120 46 118
E.E.V. F 51 204 149 47 113
Children
C.V.B. F 34 102 29 67 31
S.G.S. F 29 92 40 51 21
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DISCUSSION
Patient H.J.B. differs from most previously described
cases of familial hypobetalipoproteinemia in several
respects. First, his LDL cholesterol levels (4-8 mg/dl)
are below those generally reported, as are the levels
in two of his affected siblings (4 and 5 mg/dl, respec-
tively). Second, despite the extremely low LDL levels,
his triglyceride levels are in the normal range (91 mg/dl
on an ad lib. diet). One patient in the kindred de-
scribed by Richet et al. (35) and four patients in the
kindred described by Tamir et al. (36) had LDL cho-
lesterol levels below 10 mg/dl but these patients all had
low triglyceride values. In most previously reported
cases the degree of hypobetalipoproteinemia is par-
alleled by the degree of hypotriglyceridemia. Third,
HDL cholesterol levels in H.J.B. are distinctly low-
about one-half normal. Fourth, although there is no
history of symptomatic malabsorption, fecal fat levels
are slightly but definitely increased in H.J.B. (13-17
g/d). Finally, he shows fasting chylomicronemia and a
documented defect in chylomicron clearance. Fred-
rickson et al. (37) noted fasting chylomicronemia in
several members of one kindred when high-fat meals
were fed the preceding day and considered the pos-
sibility that a delay in fat absorption might account
for it. In the present case, both impaired chylomicron
clearance and delayed fat absorption may contribute.
The hypobetalipoproteinemia in H.J.B. appears to
result from a marked reduction in the rate of LDL pro-
duction. Fractional catabolic rate was at the upper limit
of the normal range but not high enough to account
for the low steady-state LDL levels. Daily production
of LDL apoprotein (0.65 mg/kg per d) was <10% of
normal. These data were obtained using homologous
labeled LDL prepared from plasma of a normal donor
and may not reflect faithfully the kinetics of H.J.B.'s
endogenous LDL. However, attempts to demonstrate
abnormalities in his LDL have thus far been negative.
His LDL gave a line of identity with normal LDL in
immunodiffusion and it appeared to bind normally to
LDL receptor sites on normal human skin fibroblasts.
Furthermore, studies of skin fibroblasts from patient
H.J.B. showed that his own LDL receptors are within
normal limits and under normal regulation by the LDL
levels to which they are exposed. Thus, it seems rea-
sonable to accept the low value for LDL production
derived from the use of homologous LDL. Levy et al.
(38) and Sigurdsson et al. (39) have reported low LDL
apoB synthetic rates in two other familial hypobeta-
lipoproteinemia kindreds using isologous LDL. Both
absolute and fractional catabolic rate for VLDL triglyc-
erides were low. VLDL apoB turnover has not been
directly determined but if we make the approximation
that fractional catabolic rate for VLDLapoB is the same
as that for VLDL triglyceride (it will actually be some-
what lower) we can estimate apoB turnover to be about
0.97 mg/kg per d. This low value results from both a low
fractional catabolic rate and a low apoB:triglyceride
ratio. In normal subjects apoB turnover in VLDL is
nearly the same as that in LDL i.e., 10-20 ml/kg per d
(22, 40, 41). The calculated value in H.J.B. is distinctly
low, only slightly greater than his apoB transport in
LDL (0.65 mg/kg per d). Thus the results are compatible
with the interpretation that VLDL production is ab-
normally low and that most of the patient's plasma LDL
arises from VLDL. Sigurdsson et al. (39) measured both
VLDL and LDL apoB turnover in a single patient with
hypobetalipoproteinemia. The fractional catabolic rate
for LDL was within normal limits whereas that for
VLDL was a little >50% of normal; absolute synthetic
rates of apoB were 8.7 mg/kg per d in VLDL and 5.96
mg/kg per d in LDL, values almost 10 times those in
the present case.
On a fat-free, high-carbohydrate diet H.J.B. failed to
show carbohydrate-induced elevation of plasma tri-
glycerides. Fredrickson et al. found normal carbohy-
drate induction in the affected members of their kindred
(kindred 4 [37]). An absence of carbohydrate induction
might be expected if our patient's capacity to secrete
apoB is already fully expressed. However, he actually
showed a decrease in plasma triglyceride levels on the
fat-free diet, suggesting the possibility that a significant
part of his VLDLmay have its origin from chylomicrons.
The ability of LDL to regulate cholesterol biosyn-
thesis (at the hydroxymethylglutaryl-CoA reductase
step) in cultured cells of animal and human origin is
well established (42). There is evidence from animal
studies indicatinig that this suppression is operative in
vivo (43, 44) but it is not known with certainty whether
or not synthesis in peripheral tissues in man is nor-
mally suppressed by LDL. Total sterol output in pa-
tients with abetalipoproteinemia is increased (45) but
much or all of the increase might be due to increased
hepatic synthesis due to the accompanying malabsorp-
tion and failure to make chylomicrons. The patient de-
scribed here presented the unusual combination of
normal (or nearly normal) fat absorption and chylomi-
cron formation but almost total absence of LDL. If the
relationship between intravascular and extravascular
LDL concentrations in H.J.B. is similar to that in nor-
mal and hyperlipidemic subjects (46), his extravascular
LDL cholesterol levels would be _0.5 mg/dl or 5 ,ug/dl,
i.e., below the level needed to saturate the high affinity
receptors (42). The finding of a 40% increase in total
sterol output is compatible with the conclusion that
cholesterol synthesis is normally suppressed by LDL.
Because of the wide range of normal values, however,
a firm conclusion will require additional studies of pa-
tients of this kind.
Hypobetalipoproteinemia (LDL cholesterol concen-
tration >2 SD below the normal) was present in six
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siblings (including the proband) of the nine examined:
three males and three females were affected. The pro-
band's mother and both of his children were also af-
fected. The findings are compatible with autosomal
dominant inheritance. Three of the affected siblings
had LDL cholesterol levels below 10 mgldl whereas
the other three had levels ranging from 62 to 83 mg/dl.
In the absence of other information one would have to
seriously consider the possibility that H.J.B. and his
siblings, J.Y.G., and A.L.B., are actually homozygotes
(i.e., have a double dose of a dominant allelic mutation)
whereas his mother, the other three siblings and his
daughters are heterozygotes. However, in previously
described kindreds the homozygotes have been char-
acterized by an absence of detectable LDL and by the
signs and symptoms of abetalipoproteinemia in early
childhood (5-7). Only if the mutation in the H.J.B.
kindred is distinct from that in the previously described
kindreds does the suggestion of homozygosity have
weight.
H.J.B. differs both from the other affected members
of his kindred and from most previously described
hypobetalipoproteinemic patients in that his triglyc-
eride levels are normal and he displays fasting chylo-
micronemia on many occasions. In view of his demon-
strated defect in chylomicron clearance and in the
absence of any obvious environmental factors, we con-
sidered the possibility of an abnormality in apoC-II (47)
but found none. The low apoE3/apoE2 ratio in his VLDL
may be relevant to his clearing defect. Utermann and
co-workers have shown that patients with familial dys-
betalipoproteinemia, associated with accumulation of
chylomicron "remnants", have complete or nearly com-
plete apoE3 deficiency (48). Interestingly, some sub-
jects with the complete deficiency of apoE3 do not have
hyperlipoproteinemia although their plasma shows the
characteristic abnormal "floating" betalipoprotein (49).
These patients have abnormally low plasma LDL
levels. Intermediate degrees of apoE3 deficiency (het-
erozygous state) are extremely common(49, 50) but are
not necessarily associated with hyperlipoproteinemia.
It is possible that the low apoE3/apoE2 ratio in our
patients accounts for some of the unusual features in
his case. A deficiency of apoC-III1 has been reported
in abetalipoproteinemia (4, 51) but this is the first re-
ported example in apoC-III, deficiency in hypobeta-
lipoproteinemia. Whether it represents a primary defect
or a secondary consequence of low LDL levels is not
known.
The nature of the mutant allele in hypobetalipopro-
teinemia remains unknown. The present studies and
those in two other kindreds (38, 39) show that it leads
to a marked reduction in the rate of apoB production
but how this is effected is not known. Malloy and Kane
recently described a child with hypobetalipoprotein-
emia and normal triglyceride levels (52). The clinical
syndrome in this case differs in a number of respects
from that of the present case and the apoB appears to
be structurally abnormal. Structural abnormalities in
the LDL have not been demonstrated in our case or
other cases but further efforts are in order to look for
subtle abnormalities. It is equally possible that any one
of the many steps in VLDL biosynthesis, packaging or
secretion may be involved in a regulatory sense. This
might help account for the observed variability in
expression.
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